Skip to content

Released Aug 10, 2023, before the open

10-Q filed Aug 10, 2023, 41 days after period end · 0001493152-23-027460

Q2 2023 · 10-Q
Revenue$0.00derived−100.0% vs Q2 2022−100.0% vs Q1 2023
Net Income-$3.55MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.68N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$3,955,605N/M
Operating Cash Flowderived-$3,309,597N/M
Free Cash Flowderived-$3,309,597N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$0.00$500.00K——
Net Income-$3.55M-$2.63M-$6.81M-$6.37M
EPS Diluted-$0.68-$0.61-$0.08-$0.13

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR